---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-26-000003"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:03:33.715306+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus Q4 2025 prelim rev $88.6-90.6M (+12-15%); 2026 rev guide $327-337M; targets profitability

## Summary
- Preliminary Q4 2025 net revenue $88.6M-$90.6M, 12-15% YoY growth; positive non-GAAP op income $5M-$7M.
- FY 2025 net revenue $295.5M-$297.5M, 11-12% YoY; Evolysse HA gels contributed ~8% of total revenue.
- 2026 guidance: net revenue $327M-$337M (11-13% growth); sustainable annual profitability commencing in 2026.
- Updated 2028 long-term outlook: net revenue $450M-$500M (15-19% CAGR); non-GAAP op margin 13-15%.
- Cash $53M at Dec 31, 2025, up from $43.5M at Sep 30, 2025, reflecting strong sales and expense management.

## SEC filing metadata
- accession: 0001570562-26-000003
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056226000003/0001570562-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056226000003/eols-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-26-000003
- JSON: https://secwatch.observer/filing/0001570562-26-000003.json
- Plain text: https://secwatch.observer/filing/0001570562-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.